Shire sees 24 per cent rise in revenues
Saturday 29 October 2011
Demand for hyperactivity drugs in the US drove a 24 per cent rise in third-quarter revenues for Shire.
The specialist pharmaceutical firm said its total revenues rose to $1.09bn between July and September as product sales surged by 28 per cent to $1.02bn. Alongside demand for its hyperactivity treatments, Shire also reported strong sales for its rare disease medicines. Sales of its Vyvanse attention deficit hyperactivity disorder drug were up by 32 per cent to about $200m. Drawing strength from the results, Shire chief executive Angus Russell said the company was on track to meet market expectations for the full year.
- 1 What happens to your body when you give up sugar?
- 2 Licence fee: What is the BBC charge – and how will the changes affect you?
- 3 This is what the photographer has to say about the picture of a weasel riding a woodpecker
- 4 Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
- 5 Have sex with your iPad thanks to the new sex toy no-one asked for
'Jihadi John': CAGE representative storms off Sky News accusing Kay Burley of Islamophobia
Durham Free School: 'Creationism taught at' free school facing closure
Ukip would cut billions from Scottish budget to fund English tax cuts
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
End of the licence fee: BBC to back radical overhaul of how it is funded
Ukraine crisis: Top Chinese diplomat backs Putin and says West should 'abandon zero-sum mentality'
iJobs Money & Business
£15000 - £18000 per annum: Recruitment Genius: This is a great opportunity for...
£50000 - £60000 per annum + Excellent Salary: Austen Lloyd: An outstanding new...
£20000 - £21000 per annum + uncapped commission: SThree: As a graduate you are...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...